Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

DNA methylation-based classification of sinonasal undifferentiated carcinoma.

Dogan S, Vasudevaraja V, Xu B, Serrano J, Ptashkin RN, Jung HJ, Chiang S, Jungbluth AA, Cohen MA, Ganly I, Berger MF, Momeni Boroujeni A, Ghossein RA, Ladanyi M, Chute DJ, Snuderl M.

Mod Pathol. 2019 Jun 11. doi: 10.1038/s41379-019-0285-x. [Epub ahead of print]

PMID:
31186531
2.

Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.

Sherman EJ, Dunn LA, Schöder H, Ho AL, Baxi SS, Ghossein RA, Haque SS, Sima C, Tuttle RM, Pfister DG.

Cancer. 2019 Jun 7. doi: 10.1002/cncr.32046. [Epub ahead of print]

PMID:
31174237
3.

Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging.

Turk AT, Asa SL, Baloch ZW, Faquin WC, Fellegara G, Ghossein RA, Giordano TJ, LiVolsi VA, Lloyd R, Mete O, Rosai J, Suster S, Thompson LDR, Wenig BM.

Thyroid. 2019 May;29(5):619-624. doi: 10.1089/thy.2018.0286. Epub 2019 Apr 27.

PMID:
30913992
4.

Quantitative Non-Gaussian Intravoxel Incoherent Motion Diffusion-Weighted Imaging Metrics and Surgical Pathology for Stratifying Tumor Aggressiveness in Papillary Thyroid Carcinomas.

Núñez DA, Lu Y, Paudyal R, Hatzoglou V, Moreira AL, Oh JH, Stambuk HE, Mazaheri Y, Gonen M, Ghossein RA, Shaha AR, Tuttle RM, Shukla-Dave A.

Tomography. 2019 Mar;5(1):26-35. doi: 10.18383/j.tom.2018.00054.

5.

Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.

Marcadis AR, Valderrabano P, Ho AS, Tepe J, Swartzwelder CE, Byrd S, Sacks WL, Untch BR, Shaha AR, Xu B, Lin O, Ghossein RA, Wong RJ, Marti JL, Morris LGT.

Surgery. 2019 Jan;165(1):17-24. doi: 10.1016/j.surg.2018.04.062. Epub 2018 Oct 22.

PMID:
30360906
6.

EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC.

Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, Wendel HG, Dogan S, Tamarapu PP, Blenis J, Ghossein RA, Knauf JA, Rätsch G, Fagin JA.

Cancer Discov. 2019 Feb;9(2):264-281. doi: 10.1158/2159-8290.CD-18-0606. Epub 2018 Oct 10.

PMID:
30305285
7.

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.

Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL.

J Clin Endocrinol Metab. 2019 May 1;104(5):1417-1428. doi: 10.1210/jc.2018-01478.

PMID:
30256977
8.

The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma.

Dogan S, Frosina D, Fayad M, de Oliveira TB, Alemar B, Rosenblum M, Tang LH, Hameed M, Xu B, Ghossein RA, Chute DJ, Weigelt B, Jungbluth AA.

Mod Pathol. 2019 Feb;32(2):205-215. doi: 10.1038/s41379-018-0126-3. Epub 2018 Sep 11.

PMID:
30206411
9.
10.

Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.

Patel KN, Angell TE, Babiarz J, Barth NM, Blevins T, Duh QY, Ghossein RA, Harrell RM, Huang J, Kennedy GC, Kim SY, Kloos RT, LiVolsi VA, Randolph GW, Sadow PM, Shanik MH, Sosa JA, Traweek ST, Walsh PS, Whitney D, Yeh MW, Ladenson PW.

JAMA Surg. 2018 Sep 1;153(9):817-824. doi: 10.1001/jamasurg.2018.1153.

PMID:
29799911
11.

Patterns of recurrence in oral tongue cancer with perineural invasion.

Cracchiolo JR, Xu B, Migliacci JC, Katabi N, Pfister DG, Lee NY, Patel SG, Ghossein RA, Wong RJ.

Head Neck. 2018 Jun;40(6):1287-1295. doi: 10.1002/hed.25110. Epub 2018 Mar 9.

12.

The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).

Lloyd RV, Asa SL, LiVolsi VA, Sadow PM, Tischler AS, Ghossein RA, Tuttle RM, Nikiforov YE.

Hum Pathol. 2018 Apr;74:1-4. doi: 10.1016/j.humpath.2017.12.027. Epub 2018 Jan 16. No abstract available.

PMID:
29339178
13.

Crucial parameters in thyroid carcinoma reporting - challenges, controversies and clinical implications.

Xu B, Ghossein RA.

Histopathology. 2018 Jan;72(1):32-39. doi: 10.1111/his.13335. Review.

14.

Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.

Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, Haque S, Sima CS, Cullen G, Fagin JA, Pfister DG.

Cancer. 2017 Nov 1;123(21):4114-4121. doi: 10.1002/cncr.30861. Epub 2017 Jun 29.

15.

Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene.

Montero-Conde C, Leandro-Garcia LJ, Chen X, Oler G, Ruiz-Llorente S, Ryder M, Landa I, Sanchez-Vega F, La K, Ghossein RA, Bajorin DF, Knauf JA, Riordan JD, Dupuy AJ, Fagin JA.

Proc Natl Acad Sci U S A. 2017 Jun 20;114(25):E4951-E4960. doi: 10.1073/pnas.1702723114. Epub 2017 Jun 5.

16.

Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon.

Xu B, Scognamiglio T, Cohen PR, Prasad ML, Hasanovic A, Tuttle RM, Katabi N, Ghossein RA.

Hum Pathol. 2017 Jul;65:133-139. doi: 10.1016/j.humpath.2017.05.013. Epub 2017 May 25.

17.

Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas.

Dogan S, Chute DJ, Xu B, Ptashkin RN, Chandramohan R, Casanova-Murphy J, Nafa K, Bishop JA, Chiosea SI, Stelow EB, Ganly I, Pfister DG, Katabi N, Ghossein RA, Berger MF.

J Pathol. 2017 Aug;242(4):400-408. doi: 10.1002/path.4915. Epub 2017 Jun 9.

18.

Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Historical Context, Diagnosis, and Future Challenges.

Xu B, Tallini G, Ghossein RA.

Endocr Pathol. 2017 Jun;28(2):128-138. doi: 10.1007/s12022-017-9478-3. Review. Retraction in: Endocr Pathol. 2018 Aug 7;:.

PMID:
28361392
19.

A Proposal to Redefine Close Surgical Margins in Squamous Cell Carcinoma of the Oral Tongue.

Zanoni DK, Migliacci JC, Xu B, Katabi N, Montero PH, Ganly I, Shah JP, Wong RJ, Ghossein RA, Patel SG.

JAMA Otolaryngol Head Neck Surg. 2017 Jun 1;143(6):555-560. doi: 10.1001/jamaoto.2016.4238.

20.

Outcome of Large Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.

Xu B, Tallini G, Scognamiglio T, Roman BR, Tuttle RM, Ghossein RA.

Thyroid. 2017 Apr;27(4):512-517. doi: 10.1089/thy.2016.0649. Epub 2017 Feb 24.

21.

The History of the Follicular Variant of Papillary Thyroid Carcinoma.

Tallini G, Tuttle RM, Ghossein RA.

J Clin Endocrinol Metab. 2017 Jan 1;102(1):15-22. doi: 10.1210/jc.2016-2976. Review.

PMID:
27732333
22.

White adipose tissue inflammation and cancer-specific survival in patients with squamous cell carcinoma of the oral tongue.

Iyengar NM, Ghossein RA, Morris LG, Zhou XK, Kochhar A, Morris PG, Pfister DG, Patel SG, Boyle JO, Hudis CA, Dannenberg AJ.

Cancer. 2016 Dec 15;122(24):3794-3802. doi: 10.1002/cncr.30251. Epub 2016 Aug 10.

23.

Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion.

Dogan S, Wang L, Ptashkin RN, Dawson RR, Shah JP, Sherman EJ, Michael Tuttle R, Fagin JA, Klimstra DS, Katabi N, Ghossein RA.

Mod Pathol. 2016 Sep;29(9):985-95. doi: 10.1038/modpathol.2016.115. Epub 2016 Jun 10.

24.

Metastatic solid tumors to the jaw and oral soft tissue: A retrospective clinical analysis of 44 patients from a single institution.

Owosho AA, Xu B, Kadempour A, Yom SK, Randazzo J, Ghossein RA, Huryn JM, Estilo CL.

J Craniomaxillofac Surg. 2016 Aug;44(8):1047-53. doi: 10.1016/j.jcms.2016.05.013. Epub 2016 May 15.

25.

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.

Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nosé V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle RM, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA.

JAMA Oncol. 2016 Aug 1;2(8):1023-9. doi: 10.1001/jamaoncol.2016.0386.

26.

Pediatric Differentiated Thyroid Carcinoma of Follicular Cell Origin: Prognostic Significance of Histologic Subtypes.

Balachandar S, La Quaglia M, Tuttle RM, Heller G, Ghossein RA, Sklar CA.

Thyroid. 2016 Feb;26(2):219-26. doi: 10.1089/thy.2015.0287.

27.

Novel PAX3-NCOA1 Fusions in Biphenotypic Sinonasal Sarcoma With Focal Rhabdomyoblastic Differentiation.

Huang SC, Ghossein RA, Bishop JA, Zhang L, Chen TC, Huang HY, Antonescu CR.

Am J Surg Pathol. 2016 Jan;40(1):51-9. doi: 10.1097/PAS.0000000000000492.

28.

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, Baselga J.

Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.

29.

Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules.

Marti JL, Avadhani V, Donatelli LA, Niyogi S, Wang B, Wong RJ, Shaha AR, Ghossein RA, Lin O, Morris LG, Ho AS.

Ann Surg Oncol. 2015 Nov;22(12):3996-4001. doi: 10.1245/s10434-015-4486-3. Epub 2015 Apr 11.

30.

Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma.

Wreesmann VB, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, Shaha AR, Tuttle RM, Shah JP, Patel SG, Ghossein RA.

Thyroid. 2015 May;25(5):503-8. doi: 10.1089/thy.2015.0052. Epub 2015 Mar 31.

31.

Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.

Champa D, Russo MA, Liao XH, Refetoff S, Ghossein RA, Di Cristofano A.

Endocr Relat Cancer. 2014 Oct;21(5):755-67. doi: 10.1530/ERC-14-0268. Epub 2014 Jul 10.

32.
33.

Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue.

Iyengar NM, Kochhar A, Morris PG, Morris LG, Zhou XK, Ghossein RA, Pino A, Fury MG, Pfister DG, Patel SG, Boyle JO, Hudis CA, Dannenberg AJ.

Cancer. 2014 Apr 1;120(7):983-91. doi: 10.1002/cncr.28532. Epub 2014 Jan 21.

34.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6. doi: 10.1210/jc.2013-2383. Epub 2013 Jul 5.

35.

Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells.

Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA.

Endocr Relat Cancer. 2013 Aug 21;20(5):659-67. doi: 10.1530/ERC-13-0085. Print 2013 Oct.

36.

Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression.

Ghossein RA, Katabi N, Fagin JA.

J Clin Endocrinol Metab. 2013 Aug;98(8):E1414-21. doi: 10.1210/jc.2013-1408. Epub 2013 Jun 17.

37.

Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.

Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, Fagin JA.

J Clin Endocrinol Metab. 2013 May;98(5):E829-36. doi: 10.1210/jc.2012-3933. Epub 2013 Mar 26.

38.

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA.

N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.

39.

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA.

Cancer Discov. 2013 May;3(5):520-33. doi: 10.1158/2159-8290.CD-12-0531. Epub 2013 Jan 29.

40.

Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.

Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, Dralle H, Toledo SP, Toledo RA, Morris LG, Ghossein RA, Fagin JA, Chan TA, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Nelkin BD, Ball DW.

J Clin Endocrinol Metab. 2013 Feb;98(2):E364-9. doi: 10.1210/jc.2012-2703. Epub 2012 Dec 21.

41.

Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.

Sherman EJ, Su YB, Lyall A, Schöder H, Fury MG, Ghossein RA, Haque S, Lisa D, Shaha AR, Tuttle RM, Pfister DG.

Thyroid. 2013 May;23(5):593-9. doi: 10.1089/thy.2012.0393.

42.

Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review.

Sherman EJ, Lim SH, Ho AL, Ghossein RA, Fury MG, Shaha AR, Rivera M, Lin O, Wolden S, Lee NY, Pfister DG.

Radiother Oncol. 2011 Dec;101(3):425-30. doi: 10.1016/j.radonc.2011.09.004. Epub 2011 Oct 6.

PMID:
21981877
43.

Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients.

Ricarte-Filho JC, Matsuse M, Lau C, Ryder M, Nishihara E, Ghossein RA, Ladanyi M, Yamashita S, Mitsutake N, Fagin JA.

Int J Cancer. 2012 May 1;130(9):2215-7; author reply 2217-8. doi: 10.1002/ijc.26267. Epub 2011 Aug 24. No abstract available.

44.

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.

Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA.

Oncogene. 2011 Jul 14;30(28):3153-62. doi: 10.1038/onc.2011.44. Epub 2011 Mar 7.

45.

Adrenocortical carcinoma: the influence of large vessel extension.

Turbendian HK, Strong VE, Hsu M, Ghossein RA, Fahey TJ 3rd.

Surgery. 2010 Dec;148(6):1057-64; discussion 1064. doi: 10.1016/j.surg.2010.09.024.

PMID:
21134533
46.

Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.

Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA.

Mod Pathol. 2010 Sep;23(9):1191-200. doi: 10.1038/modpathol.2010.112. Epub 2010 Jun 4.

47.

Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study.

Rivera M, Ricarte-Filho J, Patel S, Tuttle M, Shaha A, Shah JP, Fagin JA, Ghossein RA.

Hum Pathol. 2010 Feb;41(2):172-80. doi: 10.1016/j.humpath.2009.08.011. Epub 2009 Nov 13.

48.

Histologically bland "extremely well differentiated" thyroid carcinomas arising in struma ovarii can recur and metastasize.

Garg K, Soslow RA, Rivera M, Tuttle MR, Ghossein RA.

Int J Gynecol Pathol. 2009 May;28(3):222-30. doi: 10.1097/PGP.0b013e31818a2b99.

PMID:
19620939
49.

Micromedullary thyroid cancer: how micro is truly micro?

Pillarisetty VG, Katz SC, Ghossein RA, Tuttle RM, Shaha AR.

Ann Surg Oncol. 2009 Oct;16(10):2875-81. doi: 10.1245/s10434-009-0595-1. Epub 2009 Jul 1.

PMID:
19568813
50.

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA.

Cancer Res. 2009 Jun 1;69(11):4885-93. doi: 10.1158/0008-5472.CAN-09-0727.

Supplemental Content

Loading ...
Support Center